Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease

Abstract

Bone-produced fibroblast growth factor 23 (FGF23) increases in response to inflammation and iron deficiency and contributes to cardiovascular mortality in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL or lipocalin 2; LCN2 the murine homolog) is a pro-inflammatory and iron-shuttling molecule that is secreted in response to kidney injury and may promote CKD progression. We investigated bone FGF23 regulation by circulating LCN2. At 23 weeks, Col4a3^KO mice showed impaired kidney function, increased levels of kidney and serum LCN2, increased bone and serum FGF23, anemia, and left ventricular hypertrophy (LVH). Deletion of Lcn2 in CKD mice did not improve kidney function or anemia but prevented the development of LVH and improved survival in association with marked reductions in serum FGF23. Lcn2 deletion specifically prevented FGF23 elevations in response to inflammation, but not iron deficiency or phosphate, and administration of LCN2 increased serum FGF23 in healthy and CKD mice by stimulating Fgf23 transcription via activation of cAMP-mediated signaling in bone cells. These results show that kidney-produced LCN2 is an important mediator of increased FGF23 production by bone in response to inflammation and in CKD. LCN2 inhibition might represent a potential therapeutic approach to lower FGF23 and improve outcomes in CKD.

References

[1] Dussold C et al. DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease. Bone Res., 2019, 7: 12

[2] Francis C et al. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int., 2019, 96: 1346-1358

[3] Pereira RC et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone, 2009, 45: 1161-1168

[4] Faul C et al. FGF23 induces left ventricular hypertrophy. J. Clin. Investig., 2011, 121: 4393-4408

[5] Grabner A et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab., 2015, 22: 1020-1032

[6] Isakova T et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 2011, 305: 2432-2439

[7] Gutierrez OM et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med., 2008, 359: 584-592

[8] David V et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int., 2016, 89: 135-146

[9] Farrow EG et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl Acad. Sci. USA, 2011, 108: E1146-E1155

[10] Grabner A, Wolf M. Kidney to bone via bedside to bench…and back? J. Clin. Investig., 2020, 130: 1106-1108

[11] Simic P et al. Glycerol-3-phosphate is a FGF23 regulator derived from the injured kidney. TJ. Clin. Investig., 2020, 130: 1513-1526

[12] Li JY et al. Detection of intracellular iron by its regulatory effect. Am. J. Physiol. Cell Physiol., 2004, 287: C1547-C1559

[13] Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell, 2010, 141: 1006-1017

[14] Bao G et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol., 2010, 6: 602-609

[15] Cherayil BJ. The role of iron in the immune response to bacterial infection. Immunol. Res., 2011, 50: 1-9

[16] Correnti C, Strong RK. Mammalian siderophores, siderophore-binding lipocalins, and the labile iron pool. J. Biol. Chem., 2012, 287: 13524-13531

[17] Roudkenar MH et al. Neutrophil gelatinase-associated lipocalin: a new antioxidant that exerts its cytoprotective effect independent on Heme Oxygenase-1. Free Radic. Res., 2011, 45: 810-819

[18] Roudkenar MH et al. Neutrophil gelatinase-associated lipocalin acts as a protective factor against H(2)O(2) toxicity. Arch. Med. Res., 2008, 39: 560-566

[19] Hu L et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab. Investig., 2009, 89: 531-548

[20] Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem., 1993, 268: 10425-10432

[21] Mosialou I et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature, 2017, 543: 385-390

[22] Xu MJ et al. Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology, 2015, 61: 692-702

[23] Chassaing B et al. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One, 2012, 7: e44328

[24] Xu G et al. Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J. Biol. Chem., 2012, 287: 4808-4817

[25] Mishra J et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet, 2005, 365: 1231-1238

[26] Mori K et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Investig., 2005, 115: 610-621

[27] Nickolas TL et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int., 2012, 82: 718-722

[28] Bolignano D et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2009, 4: 337-344

[29] Bhavsar NA, Kottgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the atherosclerosis risk in communities (ARIC) study. Am. J. Kidney Dis., 2012, 60: 233-240

[30] Dai B et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One, 2012, 7: e44161

[31] Viau A et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Investig., 2010, 120: 4065-4076

[32] Christov M et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int., 2013, 84: 776-785

[33] Munoz Mendoza J et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin. J. Am. Soc. Nephrol., 2012, 7: 1155-1162

[34] Neuburg S et al. Genetic background influences cardiac phenotype in murine chronic kidney disease. Nephrol. Dial. Transpl., 2018, 33: 1129-1137

[35] Kim IY et al. Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol., 2018, 22: 28-34

[36] Yazdani M et al. Association between neutrophil geletinase-associated lipocalin and iron deficiency anemia in children on chronic dialysis. J. Res. Med. Sci., 2014, 19: 624-628

[37] Kestenbaum B et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol., 2005, 16: 520-528

[38] Levin A et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am. J. Kidney Dis., 1999, 34: 125-134

[39] Flo TH et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature, 2004, 432: 917-921

[40] Goetz DH et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell, 2002, 10: 1033-1043

[41] Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure, 2005, 13: 29-41

[42] Guo H, Jin D, Chen X. Lipocalin 2 is a regulator of macrophage polarization and NF-kappaB/STAT3 pathway activation. Mol. Endocrinol., 2014, 28: 1616-1628

[43] Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle, 2009, 8: 2347-2352

[44] Wilson R, Belluoccio D, Little CB, Fosang AJ, Bateman JF. Proteomic characterization of mouse cartilage degradation in vitro. Arthritis Rheum., 2008, 58: 3120-3131

[45] Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta, 2012, 1826: 129-169

[46] Lindberg S et al. Plasma neutrophil gelatinase-associated lipocalinin in the general population: association with inflammation and prognosis. Arterioscler. Thromb. Vasc. Biol., 2014, 34: 2135-2142

[47] Mishra J et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol., 2003, 14: 2534-2543

[48] Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol. Genom., 2006, 25: 375-386

[49] Berger T et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA, 2006, 103: 1834-1839

[50] Miharada K et al. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J. Cell. Physiol., 2008, 215: 526-537

[51] Miharada K, Hiroyama T, Sudo K, Nagasawa T, Nakamura Y. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J., 2005, 19: 1881-1883

[52] Bolignano D et al. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol. Dial. Transpl., 2009, 24: 3398-3403

[53] Shimada T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab., 2010, 95: 578-585

[54] Stubbs JR et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J. Bone Miner. Res., 2012, 27: 38-46

[55] Watanabe H et al. Lipocalin 2 binds to membrane phosphatidylethanolamine to induce lipid raft movement in a PKA-dependent manner and modulates sperm maturation. Development, 2014, 141: 2157-2164

[56] Meir T et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int., 2014, 86: 1106-1115

[57] Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimetal kidney failure: a bone parathyroid feedback loop. Am J. Physiol. Ren. Physiol., 2010, 299: F882-F889

[58] Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J. Biol. Chem., 2015, 290: 10447-10459

[59] Gutierrez OM et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 2009, 119: 2545-2552

[60] Mitsnefes MM et al. FGF23 and left ventricular hypertrophy in children with CKD. Clin. J. Am. Soc. Nephrol., 2018, 13: 45-52

[61] Leifheit-Nestler M et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transpl., 2016, 31: 1088-1099

[62] Marques FZ et al. Experimental and human evidence for lipocalin-2 (neutrophil gelatinase-associated lipocalin [NGAL]) in the development of cardiac hypertrophyand heart failure. J. Am. Heart Assoc., 2017, 6: e005971

[63] Singh S et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int., 2016, 90: 985-996

[64] Martin A et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology, 2008, 149: 1757-1772

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)(R01DK102815)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)